M&T Bank Corp Trims Stock Position in The Chemours Company $CC

Key Points

• M&T Bank reduced its stake in The Chemours Company by 10.7%, selling 46,822 shares and leaving it with 389,632 shares (about 0.26% of the company) valued at roughly $4.59 million.
• Chemours beat Q1 EPS expectations ($0.05 vs. -$0.05) but posted revenue of $1.38B slightly below estimates and issued softer Q2 guidance (~$1.6–1.7B); the company still has a negative net margin and carries significant leverage.
• The board declared a quarterly dividend of $0.0875/share (annualized yield ~1.5%), while analysts maintain a consensus "Hold" rating with an average target price of $21.60.

M&T Bank Corp lessened its holdings in shares of The Chemours Company (NYSE:CC - Free Report) by 10.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 389,632 shares of the specialty chemicals company's stock after selling 46,822 shares during the period. M&T Bank Corp owned approximately 0.26% of Chemours worth $4,593,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd purchased a new position in shares of Chemours during the third quarter worth $43,000. Advisory Services Network LLC acquired a new stake in Chemours during the third quarter worth about $54,000. Hantz Financial Services Inc. grew its holdings in Chemours by 334.2% during the third quarter. Hantz Financial Services Inc. now owns 4,329 shares of the specialty chemicals company's stock worth $69,000 after acquiring an additional 3,332 shares during the period. CWM LLC grew its holdings in Chemours by 32.4% during the third quarter. CWM LLC now owns 5,682 shares of the specialty chemicals company's stock worth $90,000 after acquiring an additional 1,392 shares during the period. Finally, B. Riley Wealth Advisors Inc. acquired a new position in Chemours in the second quarter valued at approximately $116,000. Hedge funds and other institutional investors own 76.26% of the company's stock.

Chemours Stock Performance

CC opened at $23.76 on Thursday. The firm has a market capitalization of $3.57 billion, a PE ratio of -9.00 and a beta of 1.47. The Chemours Company has a twelve month low of $9.13 and a twelve month high of $28.67. The firm's 50-day moving average price is $21.08 and its 200 day moving average price is $16.55. The company has a current ratio of 1.78, a quick ratio of 0.85 and a debt-to-equity ratio of 16.33.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.10. The firm had revenue of $1.38 billion for the quarter, compared to analyst estimates of $1.40 billion. Chemours had a negative net margin of 6.82% and a positive return on equity of 50.13%. Chemours's quarterly revenue was up 1.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.13 earnings per share. As a group, sell-side analysts expect that The Chemours Company will post 1.35 EPS for the current fiscal year.

Chemours Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 16th. Investors of record on Sunday, May 17th will be given a dividend of $0.0875 per share. The ex-dividend date is Friday, May 15th. This represents a $0.35 dividend on an annualized basis and a yield of 1.5%. Chemours's payout ratio is presently -14.11%.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. UBS Group upped their price objective on Chemours from $23.00 to $29.00 and gave the stock a "buy" rating in a research report on Thursday, April 9th. Mizuho set a $30.00 price objective on Chemours in a research report on Wednesday. Morgan Stanley upped their price objective on Chemours from $15.00 to $17.00 and gave the stock an "equal weight" rating in a research report on Monday, February 23rd. The Goldman Sachs Group upped their price objective on Chemours from $14.00 to $18.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 25th. Finally, BMO Capital Markets cut their price objective on shares of Chemours from $20.00 to $19.00 and set an "outperform" rating for the company in a report on Monday, February 23rd. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $21.60.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Q1 EPS beat consensus — Chemours reported $0.05 EPS, beating the Street estimate of ($0.05), which shows near-term earnings resiliency. The Chemours Company Reports First Quarter Results
• Positive Sentiment: FY revenue outlook slightly raised/confirmed around $6.0–6.1B, which is at or a touch above consensus, giving some visibility into full-year sales. Q1 2026 Earnings Call Transcript
• Positive Sentiment: Board declared a quarterly cash dividend of $0.0875/share (annualized yield ~1.5%), which may support income-focused holders. Ex-dividend and record dates were set. Chemours Announces Second Quarter Dividend
• Neutral Sentiment: Top-line was essentially flat — revenue of $1.38B was ~1% higher YoY but slightly below the $1.40B consensus, so growth is muted. Investors will watch whether volumes or pricing improve. Chemours (CC) Reports Q1 Earnings: What Key Metrics Have to Say
• Negative Sentiment: Q2 revenue guidance was issued at roughly $1.6–1.7B, which sits below consensus near $1.7B — the softer quarterly outlook likely triggered the sell-off as it suggests near-term demand weakness. Q1 2026 Earnings Call Transcript
• Negative Sentiment: Profitability and balance-sheet concerns remain: the company posted a negative net margin for the quarter and carries significant leverage, which amplifies investor sensitivity to any revenue softness. The Chemours Company Reports First Quarter Results

Chemours Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours' principal business activities are organized into three core segments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.